Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Game-changing offering leverages the power of machine learning to fill critical information gaps in the early-stage pharmaceutical pipeline.
Evaluate Ltd., a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry, today announces that it has secured additional…
“Pharma, Biotech and Medtech Half-Year Review 2020” analyses the market performance and deal landscape for the first half of 2020, focusing on the impact of COVID-19
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.
Orphan drug sales reach $242bn by 2024, according to EvaluatePharma® Orphan Drug Report 2019
Evaluate Vantage releases annual analysis of Pharma, Biotech and Medtech performance
Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2019
Evaluate Ltd. releases annual “EvaluateMedtech World Preview 2018, Outlook to 2024” in conjunction with The Medtech Conference
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.